As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...

Stock analysis is all about predictions – but as wits from Mark Twain to Yogi Berra have reminded us, predictions are hard, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

DexCom stock has fallen 41% this year ... "They are working on two products: one is a shot that you would take once a month, and the other is a pill, which is the holy grail and early studies ...

Going forward, Dexcom’s plan is to bring its promising technology to ... launching several campaigns focused on its CGM products, including its name, image, likeness (NIL) program for college athletes ...

Shelomi Sanders, the daughter of Colorado Football head coach Deion Sanders, goes in-depth with Natalie Esquire and ...

Stelo was launched this year and could be an underrated growth catalyst. It could make DexCom's products accessible to a broader market, and thus significantly expand the company's prospects ...

2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for ...